Immunocore extends its proprietary ImmTAX platform to autoimmune diseases. The company outlines plans to begin the first human trials with the drug IMC-S118AI. This drug targets the target PPI (A02). IMC-S118AI is intended for the treatment of type 1 diabetes. The ImmTAX platform is used for the development of bispecific therapies for a wide range of indications. The company's pipeline includes clinical programs in oncology and infectious diseases, as well as preclinical projects. The information is current as of September 2024. The effectiveness and safety of drugs in development have not yet been proven.